Want to join the conversation?
David Amsellem of Piper Jaffray asks about generic competition for Nitropress Isuprel. CEO Joe Papa said $VRX is expecting generic competition and added that the generic competition will occur sometime in the next 6 to 12 months for both of the products, starting with Nitropress and then later Isuprel.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.